High-Dose Transdermal Estrogen, Corticotropin-Releasing Hormone, and Postnatal Depression1

Giovanni Cizza, Philip W. Gold and George P. Chrousos

Section on Pediatric Endocrinology, DEB, NICHD, Clinical Neuroendocrinology Branch, NIMH, NIH Bethesda, Maryland 20892-1262

A.J.P. Gregoire et al. recently reported in The Lancet that high-dose transdermal estrogen is an effective treatment for postnatal depression (1). In this double-blind, placebo-controlled study, a 3-month course of 200 µg/day of 17ß-estradiol significantly improved the clinical symptomatology of severely depressed women within 1 month of treatment; its antidepressant effect lasted over 5 months.

Although the etiology of the postnatal "blues" and its more severe form, postnatal depression, is not known, several endocrine mechanisms have been proposed. We have hypothesized that these conditions may be caused by transient hypoactivation of the hypothalamic corticotropin-releasing hormone (CRH) neurons of varying degree and duration (2). This hypoactivation may be the combined result of glucocorticoid-induced suppression and estrogen deficiency.

The third trimester of pregnancy is characterized by a hyperactive hypothalamic-pituitary-adrenal (HPA) axis. This is the result of progressively increasing levels of circulating CRH of placental origin and decreasing levels of CRH-binding protein, both phenomena contributing to elevated levels of bioactive "free" CRH and, thus, hypersecretion of ACTH and cortisol (3). In addition, the elevated serum estradiol levels of pregnancy may participate in the stimulation of the HPA axis during this period (4). After delivery of the fetus and placenta, the source of CRH and estradiol is removed, and the HPA axis depends upon hypothalamic CRH secretion to maintain its activity. However, exposure to high concentrations of endogenous or exogenous glucocorticoids for more than 2 weeks has been associated with an impairment of adrenocortical function, whose central locus resides at the level of the hypothalamic CRH neuron and its higher inputs (5). This, together with postnatal estrogen deficiency, leads to a state of hypoactivation of the HPA axis, which may last from a few weeks to several months. We recently demonstrated that, indeed, in the subgroup of women who develop the postnatal blues or depression, the suppression of the HPA axis is more severe and lasts longer than that of women who have no emotional problems in the postpartum period (2). The mean plasma ACTH response to an iv bolus of 1 µg/kg of ovine (o) CRH was more severely blunted. This attenuation lasted for a longer period of time (at least 12 weeks vs. 3 weeks) in depressed than in euthymic women, suggesting a more pronounced and sustained suppression of the hypothalamic CRH neuron in this subgroup of patients (2).

CRH has been associated with the pathogenesis of depression (6). Depending on whether patients have CRH hyper- or hyposecretion, we have recognized two different subtypes of depression, melancholic depression, clinically characterized by hypophagia and hyposomnia, and atypical depression, characterized by irritability, hyperphagia, and hypersomnia (6). States such as seasonal affective disorder and the chronic fatigue/fibromyalgia syndrome are akin to atypical depression. Postnatal depression also appears to be a state of dysregulation of the hypothalamic CRH neuron characterized by CRH hyposecretion. Because the promoter of the CRH gene contains estrogen receptor-binding estrogen-responsive elements and responds positively to estrogens, we believe that the ability of 17ß-estradiol to ameliorate the symptomatology of postnatal depression may be through normalization of CRH secretion (7).

Footnotes

1 Address all correspondence to: Giovanni Cizza, MD, DEB, NICHD, NIH, Building 10, Room 10N-262, 10 Center Drive, Bethesda, Maryland 20892-1262. Back

Received October 18, 1996.

References

  1. Gregoire AJP, Kumar R, Everitt B, Henderson AF, Studd JWW. 1996 Transdermal oestrogen for treatment of severe postnatal depression. The Lancet. 347:930–933.[Medline]
  2. Magiakou MA, Mastorakos G, Rabin D, Dubbert B, Gold PW, Chrousos GP. 1996 Hypothalamic corticotropin-releasing hormone suppression during the post-partum period: implications for the increase of psychiatric manifestations in this period. J Clin Endocrinol Metab. 81:1912–1917.[Abstract]
  3. Linton EA, Perkins AV, Woods RJ, et al. 1993 Corticotropin releasing hormone-binding protein (CRH-BP): plasma levels during the third trimester of normal human pregnancy. J Clin Endocrinol Metab. 76:260–262.[Abstract]
  4. Linholm J, Schultz-Moller N. 1973 Plasma and urinary cortisol in pregnancy and during estrogen-gestagen treatment. Scand J Clin Lab Invest. 31:119–122.[Medline]
  5. Gomez MT, Magiakou MA, Mastorakos G, Chrousos GP. 1993 The pituitary corticotroph is not the rate limiting step in the postoperative recovery of the hypothalamic-pituitary-adrenal axis in patients with Cushing syndrome. J Clin Endocrinol Metab. 77:173–177.[Abstract]
  6. Chrousos GP, Gold PW. 1992 The concepts of stress and stress system disorders: overview of physical and behavioral homeostasis. JAMA. 267:1244–1252.[Abstract]
  7. Vamvakopoulos NC, Chrousos GP. 1993 Evidence of direct estrogenic regulation of human corticotropin releasing hormone gene expression. J Clin Invest. 92:1896–1902.[Medline]